- ZLN005
-
- $31.00
-
2026-04-20
- CAS:49671-76-3
- Purity: 98.59%
- Supply Ability: 10g
- ZLN-005
-
- $1.00
-
2019-09-05
- CAS:49671-76-3
- Min. Order: 1ASSAYS
- Purity: 96%
- Supply Ability: 10kg
|
| Product Name: | ZLN005 | | Synonyms: | 2-(4-TERT-BUTYLPHENYL)-1H-BENZO[D]IMIDAZOLE;2-(4-tert-Butylphenyl)-1H-benzimidazole;2-(4-tert-Butylphenyl)benzimidazole;ZLN005, >=98%;2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole;2-(4-tert-Butylphenyl)benzimidazole ZLN005;ZLN005 2-(4-tert-Butylphenyl)benzimidazole;ZLN005 | | CAS: | 49671-76-3 | | MF: | C17H18N2 | | MW: | 250.34 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 49671-76-3.mol |  |
| | ZLN005 Chemical Properties |
| Melting point | 257-258℃ | | Boiling point | 415.3±38.0 °C(Predicted) | | density | 1.102±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO: soluble10mg/mL, clear | | pka | 11.52±0.10(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19) | | InChIKey | LQUNNCQSFFKSSK-UHFFFAOYSA-N | | SMILES | [nH]1c2c(nc1c3ccc(cc3)C(C)(C)C)cccc2 |
| Hazard Codes | Xn | | Risk Statements | 22-36 | | Safety Statements | 26 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | ZLN005 Usage And Synthesis |
| Description | Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a tissue-specific and inducible transcriptional coactivator for several nuclear receptors and plays a key role in energy metabolism, hepatic gluconeogenesis, and cholesterol homoeostasis. ZLN005 is a small molecule that stimulates the expression of PGC-1α and downstream genes in skeletal muscle cells, improving glucose utilization and fatty acid oxidation at a concentration of 20 μM. Chronic administration of 15 mg/kg/day ZLN005 to diabetic db/db mice increased PGC-1α and downstream gene transcription in skeletal muscle, increasing fat oxidation and improving glucose tolerance, pyruvate tolerance, and insulin sensitivity. | | Uses | ZLN005 increaces PGC-1α and downstream gene transcription in skeletal muscles and increases fat oxidation and improved the glucose tolerance, pyruvate tolerance, and insulin sensitivity of diabetic db/db mice. | | Synthesis | The reaction was carried out in a magnetically stirred round-bottomed flask equipped with a condenser and placed in a temperature-controlled oil bath. O-phenylenediamine (2 mmol) was added to 4-tert-butylbenzyl alcohol (3 mmol) and the reaction mixture was stirred at 135 °C in an open (air) atmosphere. The reaction was monitored by TLC and after complete disappearance of the o-phenylenediamine or after the reaction had reached a predetermined time, the reaction mixture was cooled to room temperature. The crude product was purified by column chromatography on silica gel (100-200 mesh) to afford 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole. All products were structurally confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS) data. | | in vivo | ZLN005 (15 mg/kg; p.o.; per day for 4 weeks) decreases random blood glucose and fasting blood glucose levels over 4 weeks compared with lean mice[1]. | Animal Model: | Eight-week-old db/db mice[1] | | Dosage: | 15 mg/kg | | Administration: | Oral administration; per day for 4 weeks | | Result: | Random blood glucose and fasting blood glucose levels decreased significantly over 4 weeks compared with lean mice. |
| | References | [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 19, p. 3332 - 3340
[2] Tetrahedron Letters, 2014, vol. 55, # 48, p. 6520 - 6525
[3] Catalysis Letters, 2018, vol. 148, # 1, p. 30 - 40
[4] New Journal of Chemistry, 2018, vol. 42, # 8, p. 6449 - 6456 |
| | ZLN005 Preparation Products And Raw materials |
|